Nisha Rajagopal, Ph.D.
Affiliations: | 2013 | Bioinformatics and System Biology | University of California, San Diego, La Jolla, CA |
Area:
Inference of gene regulatory networks and determination of protein specificityGoogle:
"Nisha Rajagopal"Mean distance: 9.94 | S | N | B | C | P |
Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hu S, Marineau JJ, Rajagopal N, et al. (2019) Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research |
| Hu S, Marineau J, Hamman K, et al. (2019) Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo Cancer Research. 79: 4421-4421 |
| Ke N, Johannessen L, Rajagopal N, et al. (2019) Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409 |
| Johannessen LH, Hu S, Ke N, et al. (2019) Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18 |
| Rajagopal N, Hodgson G, Hu S, et al. (2018) Abstract P1-09-08:BCL2L1(BCL-XL) expression and MYC super-enhancer positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in triple negative breast cancer (TNBC) cell lines Cancer Research. 78 |
| Konstantinopoulos PA, Hodgson G, Rajagopal N, et al. (2018) Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525 |
| Hu S, Ke N, Ren Y, et al. (2017) Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors Cancer Research. 77: 1151-1151 |
| Hashimoto TB, Sherwood R, Kang DD, et al. (2016) A synergistic DNA logic predicts genome-wide chromatin accessibility. Genome Research |
| Schultz MD, He Y, Whitaker JW, et al. (2015) Corrigendum: Human body epigenome maps reveal noncanonical DNA methylation variation. Nature |
| Schultz MD, He Y, Whitaker JW, et al. (2015) Human body epigenome maps reveal noncanonical DNA methylation variation. Nature. 523: 212-6 |